10.6084/m9.figshare.c.3627356_D2.v1
Kim Papp
Kim
Papp
Robert Bissonnette
Robert
Bissonnette
Melinda Gooderham
Melinda
Gooderham
Steven Feldman
Steven
Feldman
Lars Iversen
Lars
Iversen
Jennifer Soung
Jennifer
Soung
Zoe Draelos
Zoe
Draelos
Carla Mamolo
Carla
Mamolo
Vivek Purohit
Vivek
Purohit
Cunshan Wang
Cunshan
Wang
William Ports
William
Ports
Additional file 1: of Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
Springer Nature
2016
Psoriasis
Topical
Tofacitinib
CP-690,550
Physicianâs Global Assessment
Psoriasis Area and Severity Index
PASI
Dermatology Life Quality Index
Pruritus
Itch
2016-10-03 05:00:00
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Treatment_of_plaque_psoriasis_with_an_ointment_formulation_of_the_Janus_kinase_inhibitor_tofacitinib_a_Phase_2b_randomized_clinical_trial/4412861
Figure S1. Change from baseline in DLQI through Week 16. Table S1. Serious adverse events by treatment group. Table S2. Number and percent of plasma tofacitinib concentration samples (pre-dose and post-dose) by concentration range â available data mild/moderate - post hoc. Table S3. Summary of plasma tofacitinib pharmacokinetic parameters - available data at week 4 - mild/moderate - post hoc. (DOCX 238Â kb)